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ABSTRACT
Purpose Measurement of internalization of biopharmaceuticals
targeting cell surface proteins can greatly facilitate drug develop-
ment. The objective of this study was to develop a reliable
method for determination of internalization rate constant (kint)
and to demonstrate its utility.
Methods This method utilized confocal imaging to record the inter-
nalization kinetics of fluorescence-tagged biopharmaceuticals in live-
cells and a quantitative image-analysis algorithm for kint determination.
Kint was incorporated into a pharmacokinetic-pharmacodynamic
(PK-PD) model for simulation of the drug PK profiles, target
occupancy and the displacement of endogenous ligand.
Results Themethodwas highly sensitive, allowing kint determination
in cells expressing as low as 5,000 receptors/cell, and was amenable
to adherent and suspension cells. Its feasibility in a mixed cell popu-
lation, such as whole blood, was also demonstrated. Accurate assess-
ment of the kint was largely attributed to continuous monitoring of
internalization in live cells, rapid confocal image acquisition and quan-
titative image-analysis algorithm. Translational PK-PD simulations dem-
onstrated that kint is a major determinant of the drug PK profiles, target
occupancy, and the displacement of endogenous ligand.
Conclusions The developed method is robust for broad cell
types. Reliable kint assessment can greatly expedite biopharma-
ceutical development by facilitating target evaluation, drug affinity
goal setting, and clinical dose projection.
KEY WORDS biopharmaceutical drug development .
internalization kinetics . pharmacokinetic-pharmacodynamic
modeling . image analysis
ABBREVIATIONS
ADC Antibody-drug conjugate
ADCC Antibody-dependent cell-mediated cytotoxicity
CDC Complement-dependent cytotoxicity
CFSE Carboxyfluorescein succinimidyl ester
CLL Systemic clearance of the antibody by endogenous
ligand
CLRES Systemic clearance of the antibody by
reticuloendothelial systems
IV Intravenous
kint Internalization rate constant
kint,AbR Internalization rate constants for antibody-receptor
complex AbR
kint,LR Internalization rate constants for ligand-receptor
complex LR
kint,R Internalization rate constants for unbound receptor R
koff Dissociation rate constants for antibody
koffL Dissociation rate constants for ligand
kon Association rate constants for antibody







Vc Central distribution volumes
Vp Peripheral distribution volumes
INTRODUCTION
Biopharmaceuticals targeting molecules on cell membranes
are usually internalized into the cells. Target-mediated inter-
nalization and subsequently catabolism inside the cells repre-
sent an alternative route of elimination in addition to reticu-
loendothelial, hepatic, and renal clearance pathways [1–8].
Target-mediated clearance can result in rapid elimination
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from circulation and non-linear pharmacokinetics [9–14],
which can affect drug exposure and ultimately efficacy. The
efficacy of some drugs, such as immunotoxins and antibody-
drug conjugates (ADCs), are dependent on the efficiency of
target-mediated internalization to deliver the payload to cells
[15–17]. Cell membrane targets with slow internalization
rates are generally preferred for antibody therapeutics that
are intended to elicit antibody-dependent cell-mediated cyto-
toxicity (ADCC) or complement-dependent cytotoxicity
(CDC) [18–20]. A very high rate of receptor internalization
on tumor cells can also create a barrier for drug penetration
into solid tumors [20–22]. The internalization rate of the
protein-receptor complex relative to the normal turnover rate
of the receptor can result in post-treatment upregulation or
downregulation of the receptor, which also can affect phar-
macokinetics, potency, and efficacy.
Because internalization can affect the exposure and efficacy
of biopharmaceuticals, assessment of internalization kinetics
[23] is important during research and development. The
internalization kinetics provide an important parameter for
systems pharmacology and translational pharmacokinetic-
pharmacodynamic (PK-PD) models [24, 25], which can be
used to evaluate potential drug targets, establish protein engi-
neering objectives for biopharmaceuticals and predict clinical
dose requirements [26].
The primary challenge for quantitative measurement is
direct monitoring of internalization events that allow a quan-
titative determination of the internalization kinetics of the
drug-target complex. The majority of literature publications
on receptor internalization present descriptive or qualitative
approaches [27–32]. A few published quantitative internali-
zation protocols such as acid dissociation and toxin-killing
assays measure internalization indirectly. The acid dissocia-
tion method assesses antibody internalization by quantifica-
tion of internalizedmolecules after acid removal of cell surface
molecules [33, 34], whereas the toxin-killing method assesses
internalization via cell-killing activity of internalized antibody-
toxins [35]. Although both methods quantified the extent of
internalization, they analyzed the outcomes or sequelae of
internalization rather than internalization, per se.
A fluorescence-based imaging method provides a direct
measurement of drug internalization kinetics. Fluorescence
microscopy has been extensively used to visually demonstrate
internalization of fluorescence-labeled receptors, ligands and
antibodies [36–38]. Recent development of high-speed fluo-
rescence microscopes equipped with live-cell chambers, laser-
driven fluorochrome illumination and confocal capability pro-
vided highly sensitive systems for monitoring internalization in
live cells. The advanced imaging technology combined with
an algorithm for image analysis allowed development of a
sensitive and robust method for quantification of the internal-
ization rate constant. In this manuscript, we describe the
development of this imaging method and the utility of the
internalization kinetics in the discovery and development of
biopharmaceuticals targeting cell membrane receptors.
MATERIALS AND METHODS
Materials
TF-1, H1703, THP-1 cells were from ATCC. FD-hGMR
cells transfected with humanGM-CSF receptor were supplied
by CSL Ltd (formerly Amrad, Melbourne Australia). Human
whole blood from normal healthy donors was from
Bioreclamation (Cat# HMWBNAHP, Westbury, NY).
Mavrilimumab, MEDI-575 and isotype control IgG were
fromMedImmune. Anti-interferon alpha/beta receptor chain
2 monoclonal antibody (MMHAR2) was from PBL
InterferonSource, Cat# 21385, Piscataway, NJ. Human re-
combinant GM-CSF was from R&D Systems (Cat# 215-g-
010, Minneapolis, MN). RPMI (Cat# 11875–093), DMEM
(Cat# 11965–092), Gibco® Cell Dissociation Buffer (Cat#
13151–014), 0.05% trypsin (Cat# 25300054), Hoechst 33342
(Cat# H1399), AlexaFluor® 488 (Cat# A-20181) and
AlexaFluor® 647 (A-20186) Monoclonal Antibody Labeling
Kits, CellTraceTM proliferation kit CFSE (Cat# C34554)
were from Life Technologies (Grand Island, NY). Fc receptor
blocker was from Miltenyi Biotec Inc. (Cat # 120-000-442,
Auburn, CA). Biogel P-6 gel purification resin was from Bio-
Rad Laboratories, Inc, (Cat# 150–4130, Hercules, CA).
CellCarrier 384-well microplates were from PerkinElmer
Inc. (Cat# 6007550, Waltham, MA). Cedex HiRes automat-
ed cell counter was from Innovatis AG (Bielefeld, Germany).
Confocal microplate fluorescent imager Opera was from
PerkinElmer Evotec (Hamburg, Germany). BD Pharm Lyse
buffer (Cat# 555899), BD FACSCanto II and BD LyseWash
Assistant were from BD Biosciences, San Jose, CA, USA.
Preparation of AlexaFluor Conjugates
Monoclonal antibodies, IgG isotype controls and recombi-
nant proteins were conjugated with AlexaFluor-488 or
AlexaFluor-647 dyes using the antibody labeling kits accord-
ing tomanufacturer instructions. In brief, 50–100micrograms
of an antibody or a protein in the sodium bicarbonate buffer,
pH=8.3, were incubated with reactive dye reagents under
gentle agitation at room temperature for 1 h. Unincorporated
dyes were removed by size exclusion chromatography using
purification resins and columns provided in the kits. Fluores-
cent labeling of human recombinant GM-CSF was performed
using the same fluorescent reactive reagents with 15 min
conjugation time. Excesses of reactive materials were removed
using a Biogel P-6, a purification resin for separation of GM-
CSF with M.W. of approximate 14 kDa.
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Culture and Preparation of Cells for Staining
Adherent or suspension cells were cultured in T-75 flasks in
the CO2 incubators using media recommended by ATCC or
other suppliers. TF-1 cells were cultured in RPMI-1640 con-
taining 10% fetal bovine serum (FBS) and 2 ng/mL of GM-
CSF. FD-hGMR cells were cultured in DMEM containing
10% FBS and 5 ng/mL of GM-CSF. THP-1 cells were
cultured in RPMI containing 10% FBS. Adherent H1703
cells were grown in RMPI containing 10% FBS. Cells were
split according to manufacturer instructions and seeded for
experiments.
Suspension cells were seeded using optimal cell densities a
day before the experiment. For GM-CSF deprivation, TF-1
and FD-hGMR cells were cultured overnight in the respective
cell media without addition of GM-CSF. Prior to staining,
cells were washed twice with 1x phosphate buffered saline
(PBS) using centrifugation at 1,200 rpm for 7–10 min, count-
ed and resuspended at the concentration of 3×106 cells/mL.
Adherent cells were stained using adherent or suspension
protocols. For adherent protocols, cells were seeded into rep-
licate wells in 384-well imaging plates and were grown in
complete media one day before experiment. Seeding of
30,000-50,000 cells/well resulted in confluent monolayers
after overnight culturing. Seeding densities were adjusted
based on cell doubling times if cells were cultured over a
longer period of time before experiments. On the experiment
day, cells were washed twice with 1x PBS using gentle aspira-
tion. Alternatively, adherent monolayers grown in T-75 flasks
were dissociated into cell suspension using EDTA-dissociation
buffer. Flasks with cells were washed twice with 1x PBS
followed by 30 min incubation with 10 mL of dissociation
buffer in the CO2 incubator. Detached cells were washed
twice with 1x PBS using centrifugation at 1,200 rpm for 7–
10 min. Cells were then resuspended into phenol-free RPMI
plus 0.1% BSA at concentration of 3×106 cells/mL.
Whole blood samples (70 µL) were stained with Hoechst
33,342 at 1µg/mL in the CO2 incubator for 15 min. Samples
were pre-chilled on ice and further incubated on ice with
antibodies for 1 h. Erythrocytes lysis was then performed at
room temperature with 1x BD Pharm Lyse buffer followed by
2–3 centrifugation washes with 1x PBS. Erythrocytes lysis and
washes were carried out in the BD Lyse Wash Assistant.
Resultant crude preparations of white blood cells were resus-
pended to the initial blood sample volumes using 1x PBS
containing 0.2% BSA.
Cell Staining and Analysis by Flow Cytometry
Cell suspension at 3×106 cells/mL were pre-chilled on ice,
blocked with the Fc receptor blocker for 5–10 min when
needed and then incubated with the appropriate fluorescent
conjugates for 1–2 h. In competition experiments, an
unlabeled competitor molecule was pre-incubated with the
cells for 30–60 min prior to the addition of the labeled
counterpart. Following incubation on ice for 1–2 h, unbound
fluorescent dyes were removed by 2–3 washes with ice-cold 1x
PBS by centrifugation at 4°C. Cells were then resuspended in
1x PBS plus 0.2% BSA and immediately analyzed using flow
cytometry on BD FACS Canto II. For multi-color analysis,
spectral overlap was compensated using single dye-stained
controls. A minimum of 2,500 events were acquired for cul-
tured cell lines and 2,000 events in the monocyte gate for
whole blood samples.
Measurement of Mavrilimumab Internalization using
Acid-dissociation Method
TF-1 cells at 3-6×105 cells/mL were pre-blocked with FcR
blocker on ice for 5–10 min and then incubated with 1µg/mL
of mavrilimumab-AlexaFluor-647 on ice for 1 h. Excess dye
was removed by centrifugation and cells were either main-
tained on ice (4°C sample) or transferred to the CO2 incuba-
tor to initiate internalization (37°C sample). Internalization
was carried out for two hours in the CO2 incubator. Each of
the samples were split into two aliquots and treated with 1x
PBS or acid (0.2 M acetic acid, 0.5 M NaCl, pH=2.5) at 4°C
for 10 min. Treated samples were washed twice with ice-cold
1x PBS by centrifugation, and mavrilimumab-AlexaFluor-
647 fluorescence was measured by flow cytometry using BD
FACS Canto II. Surface-localized mavrilimumab in each of
the samples was determined from the decrease of AlexaFluor-
647 signal by acid treatment. It was calculated using the
equation 1-(FLacid/FLPBS), where FLacid and FLPBS were
mavrilimumab-AlexaFluor-647 fluorescence signals of the
sample in the presence and absence of acid, respectively.
The 4°C sample was used as a “no internalization” control
and thus was considered to have 100% of mavrilimumab-
AlexaFluor-647 localized on cell surface. Therefore, internal-
ized mavrilimumab-AlexaFluor-647 was calculated as the
difference between the surface-localized mavrilimumab at
4°C and that at 37°C and expressed as percentage relative
to the value of the 4°C sample.
Cell Staining for Imaging
Cell suspension at 3×106 cells/mL were incubated for 15–
30 min with 1µM CFSE prepared in 1x PBS at 37°C in the
CO2 incubator. Unincorporated CFSE dye was removed by
two 1x PBS washes using centrifugation at 1,200 rpm for 7–
10 min at room temperature. Cells were then chilled on ice,
blocked with the Fc receptor blocker if needed and stained
with fluorescent antibodies or proteins as described for flow
cytometry staining. After removal of unbound fluorescent
reagents by centrifugation at 4°C, cells were resuspended in
PBS containing 0.2% BSA or phenol red-free medium
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containing 1% FBS. Cells were transferred into multiple wells
of 384-well imaging plate, and briefly centrifuged at
2,200 rpm for 2 min at 4°C prior to image acquisition.
Adherent cells were sequentially incubated at appropriate
temperatures with CFSE, Fc receptor blocker if needed, and
fluorescent antibodies directly in the wells of 384-well imaging
plate. Excessive dyes were removed by gentle aspiration; 50–
80 µL of imaging buffer (phenol red-free RPMI plus 1% FBS)
were added to the wells of the 384-well plate prior to image
acquisition.
For sodium azide treatment, CFSE-labeled cells were pre-
treated with 0.1% sodium azide for 30 min prior to staining
with fluorescent antibodies. Sodium azide was present during
washes and incubations.
Acquisition of Cell Images Using Opera
Stained cells in imaging plates (384-well format) were trans-
ferred into the “live-cell” chamber of the confocal fluorescence
imager Opera under the controlled conditions of 37°C, 5%
CO2 and 70% humidity to initiate and record internalization.
A series of images were acquired at indicated times. Water-
immersion objectives with 40x magnification, numerical ap-
erture of 0.9 and 60x magnification, numerical aperture 1.2
were used for image acquisition.
Excitation lasers and emission filters for sample image
acquisition were selected based on sample staining fluoro-
chromes. Hoechst dye was excited by 405 nm laser and
emission was collected in channel 1 (450±50 nm), CFSE
and FITC were excited by 488 nm laser and emission collect-
ed in channel 2 (540±75 nm) and AlexaFluor-647 was excited
by 635 nm laser and emission collected in channel 3 (690±
50 nm). If needed, dual laser excitations of 488/635 nm or
405/635 nm were used for multi-color stained samples. Prior
to image acquisition in Opera, exposure parameters, such as
voltages for laser excitations, exposure times, image binning
factors, focusing height etc., were determined using an aliquot
of the stained cells. Determined exposure parameters were
applied to automatic image acquisition using Acapella 1.0 and
Acapella 2.0 image acquisition software. Acquired image files
were spooled over to the intermediate servers until retrieval
for data processing. The raw images were exported as TIFF
format and processed using ImageJ (NIH, Bethesda, MD) and
Adobe Illustrator (Adobe, San Jose, CA).
Algorithm for Image Analysis of Internalization
Antibody-associated fluorescence in membrane and cytoplas-
mic regions of cells residing in the field of image is quantified
by an algorithm, which is a script for iterative processing of
images acquired in reference (CFSE) and signal (antibody-
AlexaFluor-647) channels of the imager. Images were proc-
essed by the algorithm using algorithm-defined parameters,
which were initially set as default values and then optimized
for each cell type and experiment.
The algorithm identifies cells as objects based on cytoplasm
staining (CFSE channel), then it constructs “membrane” and
“cytoplasm” regions around boundaries of cell objects and
finally quantifies fluorescence signals within each area. The
membrane region is generated around a cell object as a
circular ring (for round suspension cells) or as an irregular
shaped contour (for adherent cells) by extension of several
pixels in and out of the boundary of the object. The remaining
part of a cell object is denoted as cytoplasm. Since receptors
tend to cluster into spots upon internalization, fluorescence
intensity of spots was used to monitor antibody-associated
AlexaFluor-647 signals. Fluorescent spots were identified
based on intensity of fluorescence signal, its contrast to the
background, the size of fluorescent spot and other character-
istics using algorithm-based and user-adjustable parameters.
The fluorescence intensities of the qualified spots in mem-
brane and cytoplasm regions were quantified. Figure 2b shows
selected steps of image analysis using the algorithm. CFSE
staining of the image was identified as “Initial Mask (1)”. A
threshold of fluorescence intensity was applied to exclude
areas with fluorescence intensity signals below the threshold.
The remaining CFSE-stained areas were segmented into cell
objects, which were denoted as “Whole Cell (2)”. “Membrane
Region (3)” and “Cytoplasm Region (4)” were constructed
around the object boundaries using algorithm-defined param-
eters. The fluorescent spots were identified within each cell
search region. Invalid spots (green – due to contrast, yellow –
due to intensity and red – due to both) were rejected and valid
spots (white) were accepted “Spot Detection (5)”. Accepted
spots in membrane “Membrane Region Accepted Spot (6)” or
cytoplasm “Cytoplasm Region Accepted Spot (7)” region are
shown in arbitrary colors. Image analysis of adherent cells was
conducted using the same algorithm as that for suspension
cells with adjusting of cell-associated parameters to accommo-
date variable cell shapes, sizes, and fluorescence intensities.
Finally qualified membrane and cytoplasm spots were an-
alyzed to derive the algorithm output values. The fluorescence
intensities of membrane spots of all accepted cells were inte-
grated and divided by sum of the pixel area of the membrane
regions, which was used as the algorithm output value for the
membrane signal. In a similar way, the cytoplasm signal
output was derived by integrating fluorescence intensities of
cytoplasm spots of the accepted cells and dividing by the sum
pixel area of the cytoplasm regions. Several image fields per
well were acquired to ensure sufficient number of cells for
quantitative analysis. Typically, 40x lens magnification
allowed capturing of 50–100 cells per image field for all cell
types tested in this study.
Accumulation of antibody-associated fluorescence in the
cytoplasm was used to quantify antibody internalization. To
avoid under or over estimation of internalization rates relying
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strictly on signals in cytoplasm, cytoplasm signals were nor-
malized by the total cell signal at each time point using the
equation: Normalized Signal in cytoplasm=Signal (cyto-
plasm)/(Signal (cytoplasm)+Signal (membrane)). Normaliza-
tion of the data ensured comparability of internalization re-
sults determined from samples with variable total cell fluores-
cence intensities due to staining variability. Internalization
rate constants kint were calculated from internalization
time course by curve fitting of the data using the
equation: Scyt tð Þ ¼ S0; cyt þ 1−e−k int⋅tð Þ⋅Smax; cyt , where Scyt (t)
is the cytoplasmic fluorescence signal at time t; S0,cyt (t)and Smax, cyt
were initial cytoplasmic fluorescence signal and maximal signal,
respectively. The curve fitting of the data was conducted using
SigmaPlot (Systat Software Inc., San Jose, CA). The half-life of
internalization (T ½) was calculated as the ratio of ln2 and kint.
Mechanistic Pharmacokinetic-pharmacodynamic
Model
Structure of the mechanistic model is shown in Fig. 5. Dispo-
sition of an antibody and the endogenous ligand, interactions
with the target receptor, and the internalization rate constant
of antibody-receptor and ligand-receptor complexes are











































In Equation 1, Input represents the intravenous administra-
tion of the antibody into the central compartment. Vc and Vp
are the central and peripheral distribution volumes, respec-
tively. Q is the intercompartmental flow. CLRES and CLL are
the systemic clearance of the antibody by the reticuloendo-
thelial systems and the endogenous ligand, respectively. The
association constants, kon (for antibody) and konL (for ligand),
were scaled by Vc as the unit of kon and konL is related to the
concentration instead of amount. SL and S0 are the zero-order
endogenous production rate of the ligand and the target
receptor, respectively. The internalization rate constants
kint,R, kint,AbR and kint,LR are for the unbound receptor R,
the antibody-receptor complex AbR and the ligand-receptor
complex LR, respectively.
Simulations were performed using software package
NONMEM (Version 7.2, ICON Development Solutions,
Ellicott City, MD). For illustration purpose neither inter indi-
vidual variability nor assay residual error were incorporated in
the model. The antibody disposition parameters CLRES
(0.186 L/day), Vc (3.06 L), Vp (1.77 L) and Q (0.294 L/day)
were assumed the same as a typical IgG not subject to
receptor-mediated clearance [39]. The endogenous ligand
was assumed to have a baseline level of 0.01 nM, a serum
half-life of 2 h and an affinity of 0.1 nM to the target receptor,
typical for a soluble cytokine [40–43]. Upon single IV admin-
istration of the antibody, simulations were then performed for
both slow- and fast-receptor-internalization scenarios with
various assumed receptor expression levels (R0=0.1 or 0.6
nM) or antibody binding affinity (Kd=0.1, 0.3 or 1 nM).
The receptor expression level was based on analysis of clinical
PK data of several mAbs against membrane-associated recep-
tors. The binding affinity reflected the range of the in vitro
experimental data generated at MedImmune for a number of
mAbs. From confocal imaging studies, most antibody-bound
receptors had an internalization T½of approximately 30min
(e.g., GM-CSF receptor alpha and PDGF receptor alpha). On
the other hand, the internalization of some receptors, such as
IFNAR2, was much slower (~2 h). The translational simula-
tions evaluated both internalization scenarios, with a typical
internalization T ½ of 30 min or 2 h.
RESULTS
Development of an Image-based Method
for Quantification of Internalization Kinetics
Measurement of Internalization
To measure internalization, a therapeutic antibody was la-
beled with a fluorescent tag, pre-bound to target cells and its
translocation from cell surface to cytoplasm was monitored by
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fluorescence imaging. For the purpose of defining the cyto-
plasmic compartment, cells were stained with a second fluo-
rescent dye. To ensure high image quality, fluorochromes for
antibody and cytoplasm labeling were selected from the dyes
with minimal spectral overlap. Therefore, blue or green dyes
in combination with far-red dyes were considered for dual-
color staining. We first evaluated optimal fluorochromes for
antibody labeling. Commonly used AlexaFluor-488 (green) or
AlexaFluor-647 (red) dyes were conjugated to mavrilimumab,
a human IgG4 antibody directed against human GM-CSF
receptor alpha. Binding specificity of mavrilimumab-
AlexaFluor conjugates was examined in human monocytes,
which express human GM-CSF receptor alpha. Supplemen-
tary Fig. 1 shows mavrilimumab-AlexaFluor-647 bound to
CD14+ monocytes. The binding was completely blocked by
pre-incubation with an excess amount of unlabeled
mavrilimumab, demonstrating binding specificity. A similar
result was observed for mavrilimumab-AlexaFluor-488 (data
not shown). Signal intensities of mavrilimumab-AlexaFluor-
488 andmavrilimumab-AlexaFluor-647 conjugates were com-
pared in TF-1 cells expressing endogenous human GM-CSF
receptor alpha and the engineered FD-hGMR cell line over-
expressing the recombinant human receptor (Supplementary
Table I). Both cells demonstrated 5–10 fold higher signals for
mavrilimumab-AlexaFluor-647 than for mavrilimumab-
AlexaFluor-488. In addition, AlexaFluor-647 dye is known to
be less susceptible to photobleaching and the detection of its
emission is minimally affected by the autofluorescence of the
cells. Therefore, AlexaFluor-647 was selected for antibody
labeling and cytoplasm was stained using a green channel
emitting dye, carboxyfluorescein succinimidyl ester (CFSE).
Receptor-mediated internalization of mavrilimumab was
assessed in TF-1 cells. Fig.1a, b shows cells labeled with CFSE
and mavrilimumab-AlexaFluor-647 prior to and two hours post
internalization. Image overlays of CFSE (green) andAlexaFluor-
647 (red) demonstrated that AlexaFluor-647 signals were local-
ized primarily on the cell surface before initiation of internaliza-
tion (T=0) and were associated with the cytoplasm area (green)
after 2 h (T=2 h) at 37°C. Translocation of mavrilimumab-
AlexaFluor-647 fluorescence signal from cell surface to cyto-
plasm indicated receptor-mediated internalization.
To confirm that observed mavrilimumab-AlexaFluor-647
fluorescence translocation was due to internalization, the im-
aging result was compared with that using an acid-dissociation
procedure. Because acid treatment of cells only removes anti-
body from the cell surface and does not affect internalized
antibody in the cytoplasm, detection of fluorescence signal
remaining after acid treatment serves as an indirect measure-
ment of antibody internalization. TF-1 cells, pre-bound with
mavrilimumab-AlexaFluor-647, were either maintained at
4°C or incubated at 37°C for 2 h. Each of the samples was
treated with and without acid and analyzed by flow cytome-
try. The decrease in the fluorescence intensity following acid
treatment was proportional to the amount of mavrilimumab
on the cell surface. Figure 1c shows surface-localized
mavrilimumab determined for the 4°C and 37°C samples.
At 4°C, no orminimal internalization was expected and thus the
value represented 100% of surface-localized mavrilimumab.
The amount of surface-localized mavrilimumab after 2 h
incubation at 37°C was approximately 60% as compared to
that at 4°C, demonstrating antibody internalization. The per-
centage of internalized antibody calculated from the decrease of
surface-localized mavrilimumab after 2 h at 37°C relative to the
4°C sample was approximately 40% (see Materials and
Methods).
To further validate the image-based method, TF-1 cells
were treated with sodium azide (NaN3), an inhibitor of cell
metabolism and energy-dependent internalization. Treat-
ment with NaN3 inhibited intracellular translocation of
mavrilimumab-AlexaFluor-647 fluorescence signals, consis-
tent with blockade of antibody internalization (Fig. 1d, e).
Measurement of Antibody Internalization Rate Constant (kint)
To measure kint, the kinetics of cell-bound antibody trans-
location from cell surface to cytoplasm was continuously
monitored by fluorescence imaging. A series of cell images
taken over time course of mavrilimumab-AlexaFluor-647
internalization in TF-1 cells is shown in Fig. 2a. Image
overlays of CFSE (green) and AlexaFluor-647 (red) dem-
onstrated predominate mavrilimumab-AlexaFluor-647
localization on the cell surface at time zero and time-
dependent translocation of the signal into cytoplasm over
three hours at 37°C.
Acquired kinetic images were analyzed with a custom-
developed algorithm. Iterative steps of image analysis for
CFSE and antibody (AlexaFluor-647) channels were de-
scribed in detail in the Methods section and briefly summa-
rized in Fig. 2b. The algorithm first identified cells as objects
based on boundaries of cytoplasm staining (CFSE channel),
then defined “membrane” and “cytoplasm” regions around
contour of cell objects and finally quantified fluorescence
intensity within each region. Since receptors tend to cluster
upon internalization, fluorescence intensity of the spots was
quantified.
Algorithm-derived mavrilimumab-AlexaFluor-647 signals
in cytoplasm over the time course of internalization are shown
in Fig. 2c. To minimize variability of fluorescence staining
between samples and experiments, the cytoplasm fluorescence
signals were normalized to total cell fluorescence. The inter-
nalization rate constant was determined from the curve fitting
of the data shown in the time course. The T ½ of
mavrilimumab-AlexaFluor-647 internalization derived from
kint was 34±5 min. The extent of internalization shown in
Fig. 2c was consistent with that determined by the acid disso-
ciation method in Fig. 1c (approximately 40% at 2 h).
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Versatility and Robustness of the Method
The Method is Suitable for Suspension and Adherent Cells
The method and algorithm was originally developed for cells in
suspension. The suitability of the method was examined for
adherent cells. The adherent cells are usually more heteroge-
neous in sizes and shapes, leading to difficulty in object segmen-
tation for image analysis. Internalization ofMEDI-575, amono-
clonal antagonistic antibody to human PDGF receptor alpha,
was examined in adherent cell line H1703 (a non-small cell lung
cancer cell). Figure 3a-c shows cytoplasmic translocation of
MEDI-575-AlexaFluor-647 over time at 37°C. Algorithm pa-
rameters were adjusted to adapt for irregular shapes and cell size
heterogeneity of adherent cells (Fig. 3d). Kinetic images taken
over the time course of MEDI-575-AlexaFluor-647 internaliza-
tion were analyzed using the algorithm. The internalization rate
constant was determined from curve fitting of MEDI-575-
AlexaFluor-647 accumulation in cytoplasm (Fig. 3e). T ½ de-
rived from kint was 23±2 min. Measurement of MEDI-575
internalization in H1703 cells using an alternative suspension
protocol, where adherent cells were detached from the plates
prior to staining and initiation of internalization, demonstrated
comparable internalization T ½ (30±8 min). The results indi-
cated that the method and the algorithm were robust and
amenable to both adherent cells and suspension cells.
The Method is Suitable for Heterogeneous Cell Populations
We also examined internalization in whole blood samples,
which could be useful when cell lines expressing the target
are not available and when the target is expressed in
peripheral blood. Figure 4 shows staining (a) and internaliza-
tion (b) of mavrilimumab-AlexaFluor-647 in white blood cells
from crude preparations of heparin anti-coagulated human
blood. High intensity AlexaFluor-647 signals were associated
with CD14+ cells (monocytes), which represented low-
abundance cells in the total white blood cell population. This
result was consistent with concurrent analysis of the sample by
flow cytometry (data not shown). Mavrilimumab-AlexaFluor-
647 translocation from the cell surface to cytoplasm was
monitored continuously over time at 37°C and antibody
internalization was clearly demonstrated (Fig. 4b). The results
indicate that antibody internalization kinetics can be deter-
mined by this method using heterogeneous cell populations.
The Method is Suitable for Cells with Low Receptor Expression
Levels
To test the ability of the method to measure kint in cells
expressing low levels of target receptors, we examined inter-
nalization of a mouse monoclonal antibody MMHAR2 di-
rected against human interferon alpha/beta receptor 2
(IFNAR2) in THP-1 cells, known to express approximately
5,000 interferon receptors per cell [44]. Internalization T ½
was determined to be approximately 110±30 min (n=2).
Results demonstrated that this method can measure internal-
ization kinetics in cells with receptor expression levels as low as
5,000 receptors per cell.
The Method is Suitable for Monitoring Ligand Internalization
We examined if the developedmethod was amenable to assess
kint of ligands bound to cell surface receptors. GM-CSF is the
Fig. 1 Assessment of mavrilimumab-AlexaFluor-647 internalization in TF-1 cells. (a,b) Overlays of CFSE (green) and AlexaFluor-647 (red) channels for cells
stained with CFSE and 1µg/mL mavrilimumab-AlexaFluor-647 prior to (a) and after incubation at 37°C for 2 h (b) are shown.(c) Levels of surface-localized
mavrilimumab-AlexaFluor-647 in the control (4°C) and the internalization (37°C, 2 h) samples determined by an acid dissociation protocol (see Materials and
Methods). Surface-localized mavrilimumab-Alexa-647 is shown relative to the value of the 4°C sample, which represented 100% of surface binding. (d,e)
Inhibition of mavrilimumab-AlexaFluor-647 translocation to cytoplasm by sodium azide. Shown are overlays of CFSE (green) and mavrilimumab-AlexaFluor-647
(red) signals of cells treated without (d) or with 0.1% NaN3 (e) followed by 2 h incubation at 37°C. Scale bars, 10µm.
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agonistic ligand for GM-CSF receptor alpha. Similar to
mavrilimumab, GM-CSF was chemically conjugated with
AlexaFluor-647 and tested for internalization in TF-1 cells.
GM-CSF-AlexaFluor-647 demonstrated faster internalization
kinetics than the antibody with T ½ calculated to be 11±
4 min (n=2). The internalization rate constant for GM-CSF-
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AlexaFluor-647 was also evaluated in a GM-CSF receptor
over-expressing cell line, FD-hGMR. The T ½ of GM-CSF-
AlexaFluor-647 internalization was 8±2 min (n=3), which
was comparable to that estimated using TF-1 cells.
Translational PK-PD Simulations
Biopharmaceuticals targeting cell surface receptors are fre-
quently subject to target-mediated clearance, resulting in non-
linear pharmacokinetic profiles. To investigate the impact and
clinical relevance of the internalization kinetics, a mechanistic
model was constructed and used to simulate the pharmacoki-
netics of an antibody against a cell membrane receptor, the
receptor occupancy, and displaced ligand levels in humans. In
this model, the antibody and an endogenous ligand compete
for the binding to the target receptor. Upon binding to the
receptor, the antibody-receptor or ligand-receptor complex is
subsequently internalized and degraded inside the cells
(Fig. 5). The model allows for different kint for the antagonistic
antibody and agonistic ligand, and consequent alteration in
the total amount of receptors on cell membrane. For example,
when the internalization rate of antibody-bound receptors is
much slower than that of ligand-bound receptors, the pres-
ence of antibody will effectively slow down the apparent
receptor internalization process, resulting in an elevated level
of receptors on the cell membrane surface. The model can
also account for competition for receptor occupancy by ele-
vated levels of the displaced, agonistic ligand.
Translational simulations demonstrated that the internali-
zation rate, target receptor expression levels, and, to a lesser
extent, antibody binding affinity, accounted for the nonlinear
profiles of antibody PK, target receptor blockade and
Fig. 2 Measurement of mavrilimumab-AlexaFluor-647 internalization rate
constant in TF-1 cells. (a) Time course of antibody internalization presented
as an image sequence. Overlays of CFSE (green) and mavrilimumab-
AlexaFluor-647 (red) image channels at indicated time points are shown.
Scale bar, 10µm. (b) Algorithm for image analysis demonstrated using T=0
image. Representative steps of iterative analysis are depicted. Initial mask (1) –
the entire area of CFSE staining. Whole Cell (2) – the area of CFSE signals
above the threshold segmented into separate cell objects. Membrane Region
(3) – the area around the boundaries of cell objects using algorithm-defined
parameters. Cytoplasm Region (4) – the area between the internal membrane
boundary and the center of the cell object. Membrane Region Spot Detection
(5) - mavrilimumab-AlexaFluor-647 signals detected as fluorescent spots in the
membrane region and classified based on size, signal intensity, contrast and
other parameters. Accepted spots are shown in white, rejected based on
intensity - in yellow, rejected based on contrast - in green, and rejected based
on both intensity and contrast - in red. Membrane Region Accepted Spots (6)
and Cytoplasm Region Accepted Spots (7) – qualified spots in the membrane
and the cytoplasm areas (shown in arbitrary colors). Outputs were spot
fluorescence intensities in membrane and cytoplasmic regions. (c) The time
course of mavrilimumab-Alexa-647 accumulation in cytoplasm. Algorithm-
derived mavrilimumab-Alexa-647 signals at each time point are shown as
normalized to total cell fluorescence. One of the two independent
experiments is presented. Data are plotted as mean±standard deviation of
triplicate wells. Internalization rate constant (kint) was determined from curve
fitting of the fluorescence data: Scyt tð Þ ¼ S0; cyt þ 1−e−k int⋅tð Þ ⋅Smax; cyt ,
where S0,cyt (t) and Smax, cyt are initial cytoplasmic fluorescence signal and
maximal signal, respectively. T ½ calculated from kint was 34±5 min.
Fig. 3 Antibody internalization in adherent cells. (a-c) Internalization of MEDI-575-AlexaFluor-647 (1µg/mL) in H1703 cells stained with CFSE is shown at T=0
(a), T=60 min (b) and T=120 min (c). Displayed are image overlays of CFSE (green) and MEDI-575-AlexaFluor-647 (red). Scale bar, 25µm. (d) Object
identification in adherent cells by the algorithm. The algorithm utilized similar iteration steps as that used for suspension cells (shown in Fig. 2b). The cell sizes and
shapes were adjusted using user-defined parameters. The step of the algorithm, Whole Cell, which depicts identification of irregular-shaped cell objects in
adherent cells (T=0 image), is shown. (e) Time course of MEDI-575-AlexaFluor-647 internalization in H1703 cells quantified by the adherent cell algorithm. One
of the six independent experiments is presented. Data are plotted as mean±standard deviation of triplicate wells. Internalization rate constant (kint) was calculated
using equation shown in figure legend to Fig. 2c. T ½ was 23±2 min.
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displacement of the endogenous ligand (Fig. 6). Serum levels
of both antibody and the ligand decreased rapidly when the
unoccupied (free) receptor level recovered to approximately
10% of the baseline. More rapid internalization or a higher
expression of the target receptor is associated with more
pronounced receptor-mediated clearance. An antibody with
a higher affinity (lower Kd) maintains >99% target receptor
blockade for a longer period of time and enhances receptor-
mediated clearance slightly. However, this effect diminishes
when internalization is fast. These simulations demonstrate
that a quantitative assessment of internalization rate can be
important for the evaluation of target receptor “druggability”,
protein engineering goals for affinity and pharmacokinetic
properties, and the projected clinical dosing regimen.
DISCUSSION
We have developed a robust method for quantitative deter-
mination of kint for biopharmaceuticals targeting cell mem-
brane receptors by using high speed live-cell confocal imaging
technology complemented with an image analysis algorithm.
Receptor-mediated internalization is commonly observed
when targeting cell surface receptors and the kint is an impor-
tant parameter that can be incorporated into mechanistic
models describing the relationships between pharmacokinet-
ics, receptor occupancy and displaced endogenous receptor
ligand upon drug administration.
The use of most physiologically relevant conditions is im-
portant for assessment of internalization. Cells with endoge-
nously expressed receptors are preferred target cells for eval-
uating internalization kinetics. However, endogenous recep-
tor expression in many primary cells and cell lines may be as
low as 2,000 – 5,000 receptors per cell, presenting technical
challenges to internalization measurements. Our methodolo-
gy using laser-driven fluorophore illumination and high reso-
lution confocal imaging allowed measurement of internaliza-
tion kinetic of interferon receptor in THP-1 cells expressing
approximate 5,000 receptors per cell, demonstrating the suit-
ability of the method for cells expressing endogenous
receptors.
Although cells expressing endogenous receptors are fa-
vored due to their physiological relevance, cell lines
transfected with recombinant receptors at high level often
alleviate the problem of assay sensitivity. However, an
Fig. 4 Mavrilimumab-AlexaFluor-647 internalization in human blood. (a) Image overlays of cells prior to internalization: left –Hoechst (blue) and mavrilimumab-
AlexaFluor-647 (red); middle – Hoechst and CD14-FITC (green) and right - Hoechst, mavrilimumab-AlexaFluor647 and CD14-FITC. Colocalized CD14-FITC
and mavrilimumab-AlexaFluor-647 are shown in yellow. (b) Mavrilimumab-AlexaFluor-647 internalization at time 0, 60 min and 240 min. A close-up view of the
cells from the dotted frame shown in the image (a) is displayed. Scale bar, 25µm.
Fig. 5 Mechanistic model structure for PK, target receptor occupancy and
ligand displacement following antibody administration. The antibody (Ab) and
an endogenous ligand compete for the binding to the target receptor (R).
Upon binding to the receptor, the antibody-receptor and ligand-receptor
complex are subsequently internalized and degraded inside the cells as
characterized by rate constants kint, AbR and kint, LR, respectively. Dose
represents the intravenous administration of the antibody into the central
compartment. Q is the inter-compartmental flow. CLRES and CLL are the
systemic clearance of the antibody by the reticuloendothelial systems and that
of the endogenous ligand, respectively. SL and S0 are the zero-order endog-
enous production rate of the ligand and the target receptor, respectively. kon
and konL are the association rate constants for antibody and ligand, respec-
tively. koff and koffL are the dissociation rate constants for antibody and ligand,
respectively.
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engineered cell line might not be representative of the inter-
nalization kinetics of cells expressing endogenous receptors.
Comparable rate constants of GM-CSF internalization in TF-
1 cells expressing endogenous GM-CSF receptors with that in
FD-hGMR cells over-expressing receptor provided confi-
dence in using a transfected cell line for internalization mea-
surements of GM-CSF receptor. However, appropriate selec-
tion of a cell line for transfection with recombinant receptors is
critical, as not every cell line should be expected to possess
appropriate endocytic machinery. In addition, upon internal-
ization, overexpressed receptors may saturate endocytic ca-
pacity [45], leading to inaccurate estimation of internalization
rate constants.
Multi-color imaging analysis allowed monitoring
mavrilimumab-AlexaFluor-647 internalization in CD14+
monocytes using crude white blood cell preparations without
enrichment, demonstrating applicability of the developed
method to primary cells. Although primary cells are the most
relevant physiological system, they present many challenges.
Primary cells might express low levels of target receptors and
also represent low-abundance cells in a mixed cell population.
Multiple image fields should be acquired to obtain sufficient
cell numbers for low-abundance cell populations. High speed
image acquisition and multi-color imaging capability are crit-
ical for successful measurements of antibody internalization in
low-abundance cells of a mixed cell population.
Fig. 6 Simulated profiles of
antibody PK, target receptor
occupancy and displaced ligand in
humans following a single 100 mg
IV administration of an antibody
directed against a cell surface target
receptor. Fast- and slow-
internalization rates correspond to
receptor internalization T ½ of
30 min and 2 h, respectively. The
presumed affinity of the
endogenous ligand to receptor is
0.01 nM. Symbols represent the
antibody affinity (Kd=0.1, 0.3 or
1 nM). R0 is the expression level of
the receptor at baseline. As shown
in these graphs, target receptor
expression level and internalization
rate are two primary determinants
of in vivo antibody PK, target
receptor occupancy, and displaced
ligand profiles.
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Because therapeutic targets are diversely expressed in various
types of cells, the development of a method amenable to suspen-
sion and adherent cultures is imperative. Our versatile approach
allowed kint determination in both adherent and suspension cells.
Adherent cells are more difficult in image analysis due to multi-
layer topology and heterogeneity of cell morphology. Cell layers
could change and detach during extended monitoring of inter-
nalization leading to out-of-focus, low quality images. In such
cases, an alternative method is to detach adherent cells and to
maintain them in suspension culture during internalization as-
sessment. A comparable T ½ of MEDI-575 internalization in
H1703 cells determined using adherent and suspension proto-
cols, demonstrated that the method was amenable for both cell
culture conditions. Therefore, if the target cells are an adherent
cell line, an adherent protocol should be performed for greater
physiological relevance. Alternatively, the suspension protocol
could be also considered for practical and convenient purpose.
The confocal imaging methodology described offers a num-
ber of advantages over existing internalization methods. This
approach measures internalization directly rather than the out-
come of internalization. Direct measurement is generally pre-
ferred over indirect methods, which present various limitations.
For example, an acid dissociation protocol relies on the efficiency
of acid dissociation for accurate quantification of internalization.
Many factors could impact the efficiency of acid dissociation and
in turn affect accuracy of quantification. For example, some
antibodies failed to completely dissociate from the surface recep-
tors even in the presence of acid [37]. High affinity interactions,
often observed for therapeutic antibodies, may lead to inefficient
acid dissociation [46] and thus, to compromised internalization
results. Acid dissociation protocols can be used for end point
analysis but are not amenable for kinetic measurements of live
cells. In addition, acid treatments could affect the cell viability
and thus the accuracy of the analysis. A recently established
antibody-toxin approach was based on inhibition of cell prolifer-
ation upon antibody internalization and toxin-mediated cell-
killing. This approach yielded high assay sensitivities attributing
to a high potency of toxins [35]. This assay, however, is more
applicable for antibody screening rather than internalization rate
constant measurement, because toxin functional activity is de-
pendent on the cell duplication time and may not be in a linear
relationship with efficiency of internalization.
Our method is capable of continuous monitoring antibody
internalization in live cells and is a direct measurement of
internalization. It monitors the same group of cells over the time
course of internalization, significantly reducing variability.More-
over, high speed image acquisition allows recording of fast
internalization kinetics and collecting kinetic images from multi-
ple imaging fields and from replicate wells to obtain sufficient
cells for accurate internalization analysis. There are a number of
advanced live-cell fluorescence microscopes, which can also
continuously monitor live-cell internalization. However, without
fast image processing, these instruments are not capable of
capturing rapid internalization kinetics in live cells. In order to
acquire cell images at multiple time points within very short time
intervals, cell fixation is required, resulting in only end-point
measurements. Combination of fluorescence microscopy with
flow cytometry in such systems as ImageStream [47] attained the
capabilities of faster sample processing and image acquisition for
larger cell numbers.However, even these advanced systemswere
still limited to end point measurements and were restricted to
suspension cells.
Internalization of a biopharmaceutical upon binding to a cell
surface target is the underlying cause of target-mediated drug
clearance. Clinical implications include nonlinear PK when tar-
get is not fully occupied, a high dose or frequent dose adminis-
tration tomaintain target engagement, impractical subcutaneous
administration due to high dose requirements, and an econom-
ically unviable cost of goods. The internalization kinetics can also
affect the mechanism of action, such as the efficiency ADC
payload delivery to tumors, tumor penetration, ability to elicit
ADCC and CDC, and receptor upregulation or downregula-
tion. Given the lengthy and costly drug development process,
evaluation and selection of the optimal therapeutic target and
drug candidate at the preclinical stage is imperative to reduce the
development risk and increase the probability of success. For cell
surface targets, the internalization rate is critical for evaluating
the drug target and designing the optimum drug characteristics.
As demonstrated by translational simulations using a mecha-
nistic model, a cell surface target at low occupancy can effectively
eliminate the drug and endogenous ligand via target-mediated
clearance. Time to this threshold greatly depends on the target
expression level and the internalization rate. If >99% of target
blockade by a biopharmaceutical is required for maximal target
modulation, a higher binding affinity will lead to a more sub-
stantial and prolonged pharmacodynamic effect. However, the
benefit of a higher affinity diminishes when the target-mediated
clearance is very rapid (rapid internalization or high expression of
the target). While the systemic expression level of a target in vivo
might not be quantifiable until data are available from an animal
model, the internalization rate can be readily studied in vitro using
a quantitative imagingmethod.This robust and sensitivemethod
has been successfully utilized in the evaluations of a therapeutic
target and antibody affinity goal [26], characterizing the nonlin-
ear PK profiles of an antibody against GM-CSF receptor alpha
in RA patients [48], and clinical bridging of an anti-IFNAR
antibody across two disease populations [49]. The quantitative
measurement of internalization rate and advanced mechanistic
PK-PD modeling are the foundation of all these model-based
drug discovery and development practices.
CONCLUSION
A robust and versatile confocal imaging method has been
developed for measurement of internalization rate constants
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for therapeutic antibodies and other biopharmaceuticals, such
as receptor ligands. This method offers advantages over other
published approaches and is amenable to a broad range of cell
types. Internalization assessment provides useful information
for selection of drug target and for defining some of the
optimal characteristics of biopharmaceuticals, including affin-
ity and pharmacokinetic properties. The internalization rate
constant is an important parameter for mechanistic PK-PD
modeling, which has become an integral part of drug devel-
opment. The combination of internalization information and
mechanistic modeling provides valuable information for ra-
tional drug design and preclinical and clinical drug
development.
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